WallStSmart

Agilent Technologies Inc (A)vsIDEXX Laboratories Inc (IDXX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Agilent Technologies Inc generates 63% more annual revenue ($7.23B vs $4.45B). IDXX leads profitability with a 24.6% profit margin vs 19.6%. A appears more attractively valued with a PEG of 1.28. A earns a higher WallStSmart Score of 71/100 (B).

A

Strong Buy

71

out of 100

Grade: B

Growth: 6.7Profit: 8.0Value: 4.7Quality: 6.5
Piotroski: 3/9Altman Z: 1.99

IDXX

Buy

63

out of 100

Grade: C+

Growth: 6.7Profit: 9.5Value: 2.7Quality: 7.0
Piotroski: 6/9Altman Z: 5.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASignificantly Overvalued (-73.4%)

Margin of Safety

-73.4%

Fair Value

$74.34

Current Price

$135.44

$61.10 premium

UndervaluedFair: $74.34Overvalued
IDXXSignificantly Overvalued (-53.1%)

Margin of Safety

-53.1%

Fair Value

$423.77

Current Price

$562.16

$138.39 premium

UndervaluedFair: $423.77Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

A2 strengths · Avg: 9.0/10
EPS GrowthGrowth
60.0%10/10

Earnings expanding 60.0% YoY

Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

IDXX4 strengths · Avg: 9.8/10
Return on EquityProfitability
70.4%10/10

Every $100 of equity generates 70 in profit

Operating MarginProfitability
31.8%10/10

Strong operational efficiency at 31.8%

Altman Z-ScoreHealth
5.9210/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
24.6%9/10

Keeps 25 of every $100 in revenue as profit

Areas to Watch

A3 concerns · Avg: 3.7/10
P/E RatioValuation
26.0x4/10

Moderate valuation

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

IDXX3 concerns · Avg: 2.0/10
PEG RatioValuation
3.592/10

Expensive relative to growth rate

P/E RatioValuation
41.3x2/10

Premium valuation, high expectations priced in

Price/BookValuation
28.6x2/10

Trading at 28.6x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : A

The strongest argument for A centers on EPS Growth, Operating Margin. Profitability is solid with margins at 19.6% and operating margin at 23.7%. PEG of 1.28 suggests the stock is reasonably priced for its growth.

Bull Case : IDXX

The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 24.6% and operating margin at 31.8%. Revenue growth of 14.3% demonstrates continued momentum.

Bear Case : A

The primary concerns for A are P/E Ratio, Altman Z-Score, Piotroski F-Score.

Bear Case : IDXX

The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 41.3x leaves little room for execution misses.

Key Dynamics to Monitor

IDXX carries more volatility with a beta of 1.54 — expect wider price swings.

IDXX is growing revenue faster at 14.3% — sustainability is the question.

IDXX generates stronger free cash flow (234M), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

A scores higher overall (71/100 vs 63/100), backed by strong 19.6% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agilent Technologies Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.

IDEXX Laboratories Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.

Want to dig deeper into these stocks?